<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ910212-0046</DOCNO><DOCID>910212-0046.</DOCID><HL>   Business Brief -- Duramed Pharmaceuticals Inc.:   Firm Wins FDA Clearance   To Resume Output of Drug</HL><DATE>02/12/91</DATE><SO>WALL STREET JOURNAL (J), PAGE A3</SO><CO>   DRMD</CO><IN>DRUG MANUFACTURERS (DRG)</IN><GV>FOOD AND DRUG ADMINISTRATION (FDA)</GV><LP>   Duramed Pharmaceuticals Inc. said it was cleared by theFood and Drug Administration to resume production ofmethylprednisolone, a steroid used for the treatment ofarthritis or muscular disorders.   The Cincinnati-based generic drug maker said the drug haspotential sales of about $25 million.</LP><TEXT>   Duramed, which had to suspend shipments of most of itsproducts for the past four months, said it also is recallingany remaining conjucted estrogen product that it didn'treceive in a recall last year. The company said that thetablets can fail to dissolve correctly but that the problemdoesn't pose any health risks.   E. Thomas Arington, chairman and chief executive officer,said he couldn't estimate the cost of the recall. But he saidthe action, combined with the suspension of shipments ofother major products, caused a fourth-quarter loss.   A year earlier, Duramed posted a loss of $5.3 million, or86 cents a share, on sales of $5 million. The loss included apre-tax charge of $750,000 related to litigation.</TEXT></DOC>